Repository logo
 
Publication

Current and future aspects of TIM-3 as biomarker or as potential targeted in non-small cell lung cancer scope: is there a role in clinical practice?

2020Journal article Open access
Simple item page
dc.contributor.authorDe Mello, Ramon Andrade
dc.contributor.authorZhu, Jin-Hui
dc.contributor.authorIavelberg, Jairo
dc.contributor.authorPotim, Artur Henrique
dc.contributor.authorSimonetti, Débora
dc.contributor.authorSilva Jr, José Antônio
dc.contributor.authorCastelo-Branco, Pedro
dc.contributor.authorPozza, Daniel Humberto
dc.contributor.authorTajima, Carla Chizuru
dc.contributor.authorTolia, Maria
dc.contributor.authorAntoniou, Georgio
dc.date.accessioned2021-02-11T14:58:37Z
dc.date.available2021-02-11T14:58:37Z
dc.date.issued2020
dc.description.abstractLung cancer is an aggressive disease with a high rate of mortality (1). Non-small cell lung cancer (NSCLC) constitutes approximately 85% of all histology types (2). In the 1990’s, chemotherapy was the standard of care for the treatment of metastatic NSCLC (3). Since 2005, targeted therapies have emerged as a new cornerstone in the treatment of NSCLC. These include epidermal growth factor receptor tyrosine kinase inhibitors (EGFRTKI) such as gefitinib, erlotinib, afatinib, osimertinib, and dacomitinib (4) as well as the anaplastic lymphoma kinase (ALK) inhibitors crizotinib, alectinib, ceritinib, brigatinib and lorlatinib (5,6). Improving our understanding of tumor biology has therefore become a fundamental issue among oncologists to optimize these novel treatment strategies (7). In 2018, James P. Allison and Tasuku Honjo (8) won the Nobel prize for their research on the mechanisms of the tumor immune escape, which led to the first immunotherapy drugs to be utilized in clinical practice: nivolumab and ipilimumab (3,9). The Karolinska Institute Nobel Prize Committee declared that Allison and Honjo’s findings constituted the fourth cornerstone of cancer treatment, alongside surgery, radiotherapy and chemotherapy (1,9).pt_PT
dc.description.sponsorshipNational Council for Scientific and Technological Development (CNPq) 402621/2016-6pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.doi10.21037/tlcr-20-625pt_PT
dc.identifier.issn2218-6751
dc.identifier.urihttp://hdl.handle.net/10400.1/15075
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherAME Publishingpt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.titleCurrent and future aspects of TIM-3 as biomarker or as potential targeted in non-small cell lung cancer scope: is there a role in clinical practice?pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage2314pt_PT
oaire.citation.issue6pt_PT
oaire.citation.startPage2311pt_PT
oaire.citation.titleTranslational Lung Cancer Researchpt_PT
oaire.citation.volume9pt_PT
person.familyNamede Mello
person.familyNameCastelo-Branco
person.givenNameRamon Andrade
person.givenNamePedro
person.identifier.ciencia-idE015-7F8F-5CA1
person.identifier.orcid0000-0002-9640-4573
person.identifier.orcid0000-0002-3453-3978
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication53ee625f-c5c3-468b-85bb-4cef5ad36928
relation.isAuthorOfPublicationbb25b5ad-1769-42be-a7d3-8fe76215aa23
relation.isAuthorOfPublication.latestForDiscovery53ee625f-c5c3-468b-85bb-4cef5ad36928

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
tlcr-09-06-2311.pdf
Size:
162.62 KB
Format:
Adobe Portable Document Format
Download

Collections

FCB2-Artigos (em revistas ou actas indexadas)